Skip to main navigation Skip to search Skip to main content

von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy

  • Karoline Rutter
  • , Alexandra Etschmaier
  • , Monika Ferlitsch
  • , Andreas Maieron
  • , Stephanie Hametner
  • , Thomas Horvatits
  • , Rafael Paternostro
  • , Petra Salzl
  • , Thomas Reiberger
  • , Markus Peck-Radosavljevic
  • , Peter Quehenberger
  • , Harald Hofer
  • , Michael Trauner
  • , Peter Ferenci
  • , Arnulf Ferlitsch

Research output: Journal article (peer-reviewed) › Journal article

Abstract

BACKGROUND: Treatment of chronic hepatitis C virus (HCV) infection was revolutionized within the last years. Interferon free antiviral regimens are not accessible without limitations. Combination of peginterferon/ribavirin with first generation direct acting antivirals is less effective and associated with serious adverse events.

AIM: We have shown that vWF-Ag is associated with portal hypertension and treatment response to PEG/RBV and we evaluated if vWF-Ag is a predictive marker for treatment response and safety in patients with triple therapy.

METHODS: 222 HCV-GT 1 patients and DAA based triple therapy were included in this retrospective, multicenter study.

RESULTS: Median vWF-Ag levels were 167.0% [IQR: 124.0-210.0%]. Significantly higher levels were seen in patients without SVR; median 190% [IQR: 146.0-259.5%] versus SVR: 142.5% [IQR: 114.3-196.8%], p<0.001. Furthermore levels of vWF-Ag were identified as independent predictor of non SVR; (OR: 1.009; 95%CI: 1.016-1.3, p=0.005). In patients with cirrhosis elevated vWF-Ag levels were associated with increased incidence of SAEs (OR: 1.016; 95%CI: 1.004-1.028; p=0.007). Best cut off for prediction of SAEs was vWF-Ag>281.5% with a sensitivity of 78% and a specificity of 90%.

CONCLUSION: Baseline vWF-Ag levels predict outcome of DAA based treatment in HCV-1 patients and identify patients with a risk of SAEs. Therefore vWF-Ag may be an additional marker for selecting patients for interferon free therapeutic regimens.

Original languageEnglish
Pages (from-to)1194-1199
Number of pages6
JournalDigestive and Liver Disease
Volume48
Issue number10
DOIs
Publication statusPublished - 01 Oct 2016
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Adult
  • Antiviral Agents/adverse effects
  • Austria
  • Biomarkers
  • Drug Therapy, Combination
  • Female
  • Hepacivirus/genetics
  • Hepatitis C, Chronic/blood
  • Humans
  • Interferon-alpha/adverse effects
  • Liver Cirrhosis/blood
  • Male
  • Middle Aged
  • Multivariate Analysis
  • ROC Curve
  • Regression Analysis
  • Retrospective Studies
  • Ribavirin/adverse effects
  • von Willebrand Factor/analysis

Fingerprint

Dive into the research topics of 'von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy'. Together they form a unique fingerprint.

Cite this